The 63-year-old, who drove snowplows and hauled heavy equipment for Howard County, Maryland, was diagnosed with non-arteritic anterior ischemic optic neuropathy, called NAION, thought to result from reduced blood flow to the optic nerve
The FDA includes all the GLP-1s from above in the same medicine classification and is evaluating reports of suicidal thoughts or actions in people taking GLP-1s
Finally, the researchers point out that the profile of people who are using GLP-1 medications to lose weight will continue to evolve as their effectiveness becomes better understood, and we have no way to predict how the larger pattern of food consumption in the United States will evolve with that profile
The FDA approved semaglutide for weight loss in June 2021
If youre considering a GLP-1 medication, well look at your health history, goals, and potential side effects to determine if its the right option for you
This allows patients to receive comprehensive information about the effectiveness of these medications, as well as advice about possible side effects
